# EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC

> **NCT07647289** · PHASE2 · RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 58 (estimated)

## Conditions studied

- Muscle-Invasive Bladder Cancer (MIBC)

## Interventions

- **DRUG:** enfortumab vedotin (EV)
- **DRUG:** Toripalimab
- **DRUG:** Gemcitabine (Chemotherapy)
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07647289
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2027-04
- **Final completion:** 2028-12
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07647289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07647289, "EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07647289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*